民生证券股份有限公司 声 明 民生证券股份有限公司（以下简称"民生证券"、"保荐机构"或"本保荐机 构"）接受博瑞生物医药（苏州）股份有限公司（以下简称"博瑞医药"、"上市 公司"或"公司"）的委托，就发行人向特定对象发行股票并在科创板上市事项 （以下简称"本次发行"）出具本发行保荐书。 关于博瑞生物医药（苏州）股份有限公司 向特定对象发行股票 之 发行保荐书 保荐人（主承销商） （ 中国(上海)自由贸易试验区浦明路 8 号） 二〇二五年七月 博瑞生物医药（苏州）股份有限公司 向特定对象发行股票之发行保荐书 本保荐机构及保荐代表人根据《中华人民共和国公司法》（下称"《公司法》"）、 《中华人民共和国证券法》（下称"《证券法》"）、《证券发行上市保荐业务管理办 法》（下称"《保荐管理办法》"）、《科创板上市公司证券发行注册管理办法（试行）》 （下称"《注册管理办法》"）、《上海证券交易所科创板股票上市规则》（下称"《股 票上市规则》"）等有关法律、行政法规和中国证券监督管理委员会（下称"中国 证监会"）、上海证券交易所的规定，诚实守信，勤勉尽责，严格按照依法制订的 业务规则、行业执业规范和道德准则出具本发行保荐 ...

北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层 邮编：100025 关于 博瑞生物医药（苏州）股份有限公司 2024 年度向特定对象发行 A 股股票 之 法律意见书 北京市竞天公诚律师事务所 34th Floor, Tower 3, China Central Place, 77 Jianguo Road, Chaoyang District, Beijing 100025, China 电话/Tel: +86 10 5809 1000 传真/Fax: +86 10 5809 1100 网址/Website: http:// www.jingtian.com 二〇二五年七月 | 释 义 | 2 | | --- | --- | | 正 文 | 6 | | 一、 | 本次发行及上市的批准和授权 6 | | 二、 | 发行人本次发行及上市的主体资格 8 | | 三、 | 本次发行及上市的实质条件 8 | | 四、 | 发行人的设立 9 | | 五、 | 发行人的独立性 11 | | 六、 | 发行人的主要股东、控股股东及实际控制人 14 | | 七、 | 发行人的股本及其演变 15 | | 八、 | ...

民生证券股份有限公司 关于博瑞生物医药（苏州）股份有限公司 向特定对象发行股票 之 上市保荐书 保荐人（主承销商） （中国（上海）自由贸易试验区浦明路 8 号） 二〇二五年七月 博瑞生物医药（苏州）股份有限公司 向特定对象发行股票之上市保荐书 博瑞生物医药（苏州）股份有限公司 向特定对象发行股票之上市保荐书 声 明 本保荐机构及保荐代表人根据《中华人民共和国公司法》（下称"《公司法》"）、 《中华人民共和国证券法》（下称"《证券法》"）、《证券发行上市保荐业务管理 办法》（下称"《保荐管理办法》"）、《科创板上市公司证券发行注册管理办法（试 行）》（下称"《注册管理办法》"）、《上海证券交易所科创板股票上市规则》（下 称"《股票上市规则》"）等有关法律、行政法规和中国证券监督管理委员会（下 称"中国证监会"）、上海证券交易所的规定，诚实守信，勤勉尽责，严格按照 依法制订的业务规则、行业执业规范和道德准则出具本上市保荐书，并保证所出 具文件的真实性、准确性和完整性。 本上市保荐书中无特别指明的简称与募集说明书相同，部分合计数与各加数 直接相加之和可能存在尾数上的差异，该等差异系因数据四舍五入所致。 3-2-1 ...

Group 1 - The core viewpoint is that the recent rebound in the Sci-Tech Innovation Board is driven by two main factors: the opening up of overseas computing power targets and the implementation of AI plans in the US, which strengthens the logic of domestic substitution [1] - The AI industry chain continues to catalyze growth, with new models like GPT-5.0 and DeepSeek R2 expected to provide effective support [1] - Since July, major domestic and international companies have released performance reports, showing a clear growth trend driven by AI, with high demand for AI computing power and continuous introduction of significant technological events [1] Group 2 - The Sci-Tech 100 ETF fund closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board 100 Index, which selects 100 securities with medium market capitalization and good liquidity from the Sci-Tech Innovation Board [2] - As of July 31, 2025, the top ten weighted stocks in the Sci-Tech Innovation Board 100 Index account for 23.52% of the index, including companies like Borui Pharmaceutical and BeiGene [2]

Investment Rating - The report maintains a rating of "Overweight" for the pharmaceutical and biotechnology industry [1] Core Insights - The report highlights the promising opportunities in the domestic oral weight-loss drug market, particularly recommending companies such as Borui Pharmaceutical and Gilead Sciences as key players [1][2] - The GLP-1 drug market is expected to see significant growth, with projections indicating a market size exceeding $150 billion by 2030, driven by increasing demand and new product approvals [6][12] - The report emphasizes the strong performance of innovative drugs, particularly GLP-1 and PD-1/VEGF dual antibodies, and suggests a focus on companies like Borui Pharmaceutical, Gilead Sciences, and others for investment [2][12] Summary by Sections Industry Performance - The A-share pharmaceutical index has shown a year-to-date increase of 21.3%, while the Hang Seng Biotechnology Index has surged by 87.2% [6][11] - Recent stock performance indicates a mixed trend, with notable gains in companies like Nanmo Biotechnology (+42%) and Haichen Pharmaceutical (+41%), while others like Nanxin Pharmaceutical (-19%) and Qizheng Tibetan Medicine (-16%) faced declines [11] Sub-industry Recommendations - The report ranks preferred sub-industries as follows: Innovative Drugs > Research Services > CXO > Traditional Chinese Medicine > Medical Devices > Pharmacies [2][12] - Specific stock recommendations include: - From the GLP-1 perspective: Borui Pharmaceutical, Gilead Sciences, and others [2][12] - From the PD-1/VEGF dual antibody perspective: Kangfang Biotech, Shenzhou Cell, and others [2][12] - From a low valuation perspective: Zoli Pharmaceutical, Dong'e Ejiao, and others [2][12] Market Dynamics - The report notes that the GLP-1 drug market is significantly underestimated, with companies like Borui Pharmaceutical and Gilead Sciences expected to emerge as major players with potential market capitalizations in the hundreds of billions [6][12] - The report also discusses the competitive landscape, highlighting the rapid growth of drugs like Eli Lilly's Mounjaro and Novo Nordisk's Wegovy, which have seen substantial sales increases [17][22] Financial Performance - Novo Nordisk reported a revenue of approximately $22.9 billion for the first half of 2025, reflecting an 18% year-on-year growth, driven by strong sales of its GLP-1 products [17][22] - Eli Lilly's revenue for the same period reached $28.3 billion, marking a 41% increase, with Mounjaro and Zepbound leading the sales growth [22][23]

Group 1 - The core transaction of Borui Pharmaceutical on August 8 involved a volume of 18,400 shares and a transaction amount of 2.1129 million yuan, with a transaction price of 114.83 yuan [2] - The buyer was China International Capital Corporation's Fuzhou Wusi Road Securities Branch, while the seller was China International Financial Co., Ltd.'s Beijing Jianguomen Outer Street Securities Branch [2] - In the last three months, Borui Pharmaceutical has recorded a total of 16 block trades, amounting to 156 million yuan [2] Group 2 - On the same day, Borui Pharmaceutical closed at 114.83 yuan, reflecting a 6.82% increase, with a turnover rate of 2.99% and a total transaction amount of 1.412 billion yuan [2] - The net inflow of main funds for the day was 127 million yuan, and the stock has increased by 15.70% over the past five days, with a total net inflow of 726 million yuan [2] - The latest margin financing balance for the stock is 2.387 billion yuan, which has increased by 555 million yuan over the past five days, representing a growth rate of 30.28% [2]

Quantitative Models and Construction Methods 1. Model Name: 250-Day New High Distance Model - **Model Construction Idea**: This model tracks the distance of stock prices or indices from their 250-day high to identify market trends and hotspots. It is based on the momentum and trend-following strategy, which has been proven effective in various studies[11][19]. - **Model Construction Process**: The 250-day new high distance is calculated using the formula: $ 250\ Day\ New\ High\ Distance = 1 - \frac{Close_t}{ts\_max(Close, 250)} $ Where: - $ Close_t $ is the latest closing price - $ ts\_max(Close, 250) $ is the maximum closing price over the past 250 trading days If the latest closing price reaches a new high, the distance is 0. If the price has fallen from the high, the distance is a positive value representing the percentage drop[11]. - **Model Evaluation**: This model effectively identifies stocks or indices with strong momentum and highlights market leaders during upward trends[11][19]. 2. Model Name: Stable New High Stock Screening Model - **Model Construction Idea**: This model focuses on identifying stocks that exhibit stable momentum characteristics, such as smooth price paths and consistent new highs, which are less likely to be influenced by extreme short-term fluctuations[25]. - **Model Construction Process**: The screening process involves the following steps: 1. **Analyst Attention**: Stocks must have at least five "Buy" or "Overweight" ratings in the past three months[27]. 2. **Relative Strength**: Stocks must rank in the top 20% of the market based on their 250-day price performance[27]. 3. **Price Stability**: Stocks are scored based on two indicators: - **Price Path Smoothness**: Measured by the ratio of price displacement to the total price movement over the past 120 days[25][27]. - **New High Consistency**: The average 250-day new high distance over the past 120 days[27]. 4. **Trend Continuity**: The average 250-day new high distance over the past five days is used to select the top 50 stocks[27]. - **Model Evaluation**: This model emphasizes the importance of smooth momentum and consistent trends, which are often overlooked by investors, leading to stronger momentum effects[25][27]. --- Backtesting Results of Models 1. 250-Day New High Distance Model - **Indices' 250-Day New High Distance**: - Shanghai Composite Index: 0.12% - Shenzhen Component Index: 3.19% - CSI 300: 3.55% - CSI 500: 0.53% - CSI 1000: 0.35% - CSI 2000: 0.23% - ChiNext Index: 8.48% - STAR 50 Index: 7.39%[12][32] 2. Stable New High Stock Screening Model - **Selected Stocks**: 50 stocks were identified, including Borui Pharmaceutical, Shenghong Technology, and Huaguang Energy[28][33]. - **Sector Distribution**: - Manufacturing: 18 stocks - Cyclical: 13 stocks - Leading industries: Machinery in manufacturing and basic chemicals in cyclical sectors[28][33] --- Quantitative Factors and Construction Methods 1. Factor Name: 250-Day New High Distance - **Factor Construction Idea**: This factor measures the relative position of a stock's closing price to its 250-day high, capturing momentum and trend-following characteristics[11]. - **Factor Construction Process**: The formula is the same as the 250-Day New High Distance Model: $ 250\ Day\ New\ High\ Distance = 1 - \frac{Close_t}{ts\_max(Close, 250)} $ - $ Close_t $: Latest closing price - $ ts\_max(Close, 250) $: Maximum closing price over the past 250 trading days[11]. - **Factor Evaluation**: This factor is effective in identifying stocks with strong upward momentum and market leadership potential[11][19]. 2. Factor Name: Price Path Smoothness - **Factor Construction Idea**: This factor evaluates the stability of a stock's price movement over time, favoring stocks with less volatile momentum[25]. - **Factor Construction Process**: - **Price Path Smoothness**: Calculated as the ratio of price displacement to the total price movement over the past 120 days[25][27]. - **Factor Evaluation**: Smooth price paths are associated with stronger momentum effects due to reduced investor attention and reaction[25]. 3. Factor Name: New High Consistency - **Factor Construction Idea**: This factor measures the consistency of a stock's new highs over time, emphasizing sustained upward trends[27]. - **Factor Construction Process**: - **New High Consistency**: The average 250-day new high distance over the past 120 days[27]. - **Factor Evaluation**: Consistent new highs indicate strong and sustained momentum, making this factor valuable for trend-following strategies[27]. --- Backtesting Results of Factors 1. 250-Day New High Distance Factor - **Indices' 250-Day New High Distance**: - Shanghai Composite Index: 0.12% - Shenzhen Component Index: 3.19% - CSI 300: 3.55% - CSI 500: 0.53% - CSI 1000: 0.35% - CSI 2000: 0.23% - ChiNext Index: 8.48% - STAR 50 Index: 7.39%[12][32] 2. Price Path Smoothness Factor - **Selected Stocks**: 50 stocks were identified, including Borui Pharmaceutical, Shenghong Technology, and Huaguang Energy[28][33]. - **Sector Distribution**: - Manufacturing: 18 stocks - Cyclical: 13 stocks - Leading industries: Machinery in manufacturing and basic chemicals in cyclical sectors[28][33] 3. New High Consistency Factor - **Selected Stocks**: Same as the Price Path Smoothness Factor, as this factor is part of the screening process for stable new high stocks[28][33].

8月8日，博瑞医药大宗交易成交1.84万股，成交额211.29万元，占当日总成交额的0.15%，成交价114.83元，较市场收盘价114.83元持平。 | 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( * ) 买入营业部 | | | | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-08 | 博瑞医药 | 688166 | 114.83 211.29 | 1.84 | 中国中金财富证券 | 中国国际金融股份 | | | | | | | | 有限公司福州五四 | 有限公司北京建国 | | | | | | | | 路证券营业部 | 门外大街证券营业 | | ...

Market Overview - On August 8, the chemical pharmaceutical sector rose by 0.24% compared to the previous trading day, with Lianhuan Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3635.13, down 0.12%, while the Shenzhen Component Index closed at 11128.67, down 0.26% [1] Stock Performance - Notable declines in individual stocks include: - Shanghai Yizhong: closed at 72.23, down 5.42% with a trading volume of 80,000 shares and a turnover of 573 million yuan - Yifang Bio: closed at 39.80, down 5.37% with a trading volume of 203,000 shares and a turnover of 818 million yuan - Qianhong Pharmaceutical: closed at 10.19, down 4.77% with a trading volume of 1,197,800 shares and a turnover of 1.23 billion yuan [1] Capital Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 230 million yuan from institutional investors and a net outflow of 93.16 million yuan from retail investors, while retail investors saw a net inflow of 323 million yuan [1] - Key stocks with significant capital flow include: - Meinuohua: net inflow of 236 million yuan from institutional investors, with a 18.01% share - Lianhuan Pharmaceutical: net inflow of 197 million yuan from institutional investors, with a 13.40% share [2] - Other notable stocks include Han Yu Pharmaceutical and Bo Rui Pharmaceutical, with net inflows of 171 million yuan and 131 million yuan from institutional investors, respectively [2]

作者：金股通 本文源自：金融界 沪深两市数据显示，8月7日，融资净买入前十的股票分别为：寒武纪（5.33亿元）、北方稀土（4.07亿 元）、硕贝德（2.95亿元）、东山精密（2.57亿元）、太辰光（2.02亿元）、东方财富（2.01亿元）、博 瑞医药（1.90亿元）、西部证券（1.81亿元）、盛和资源（1.80亿元）、东信和平（1.69亿元）。 ...